ACE and metabolic dysfunction-associated steatotic liver disease: Patients with MASLD also had a higher prevalence of hypertension and were more frequently treated with metformin, angiotensin‐converting enzyme inhibitors (ACEIs) or angiotensin II receptor antagonists (ARBs).